Results 61 to 70 of about 10,287,555 (319)

Clinical and immunologic features in severe and moderate Coronavirus Disease 2019.

open access: yesJournal of Clinical Investigation, 2020
BACKGROUND Since December 2019, an outbreak of Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, and is now becoming a global threat.
Guang Chen   +19 more
semanticscholar   +1 more source

Coronavirus Disease 2019 and Cardiac Arrhythmias

open access: yesEuropean Cardiology Review, 2020
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a very contagious virus, has led to the coronavirus disease 2019 (COVID-19) pandemic.
Antoni Martínez-Rubio   +3 more
doaj   +1 more source

Safety Recommendations for Evaluation and Surgery of the Head and Neck During the COVID-19 Pandemic [PDF]

open access: yes, 2020
Importance The rapidly expanding novel coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2, has challenged the medical community to an unprecedented degree.
Chinn, Steven B.   +13 more
core   +1 more source

Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 — COVID-NET, 14 States, March 1–30, 2020

open access: yesMMWR. Morbidity and mortality weekly report, 2020
Since SARS-CoV-2, the novel coronavirus that causes coronavirus disease 2019 (COVID-19), was first detected in December 2019 (1), approximately 1.3 million cases have been reported worldwide (2), including approximately 330,000 in the United States (3 ...
S. Garg   +37 more
semanticscholar   +1 more source

Association of infection-induced antibody levels with risk of subsequent SARS–COV-2 reinfection among healthcare professionals, Rhode Island, 1 March 2020–17 February 2021

open access: yesMicrobiology Spectrum
Numerous studies have investigated vaccine-induced correlates of protection (CoP) against severe acute respiratory syndrome–coronavirus 2 (SARS–CoV-2) infection, but data on infection-induced CoP are limited.
Jianrong Shi   +9 more
doaj   +1 more source

Coronavirus Disease 2019-Associated Coagulopathy

open access: yesMicroorganisms, 2022
Coronavirus disease 2019 (COVID-19)-associated coagulopathy is an acute illness characterized by thrombosis with or without hemorrhage after COVID-19 infection.
Jun-Won Seo   +3 more
doaj   +1 more source

Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) — United States, February 12–March 16, 2020

open access: yesMMWR. Morbidity and mortality weekly report, 2020
Globally, approximately 170,000 confirmed cases of coronavirus disease 2019 (COVID-19) caused by the 2019 novel coronavirus (SARS-CoV-2) have been reported, including an estimated 7,000 deaths in approximately 150 countries (1).
Centers for Disease Control and Prevention CDC COVID-19 Response Team
semanticscholar   +1 more source

Seroprevalence of SARS-CoV-2 IgG antibodies in children seeking medical care in Seattle, WA June 2020 to December 2022

open access: yesMicrobiology Spectrum
Seroprevalence studies play an important role in estimating the number of children infected with SARS-CoV-2. We report SARS-CoV-2 seroprevalence in children seeking medical care for any reason at a free-standing pediatric hospital in Seattle, WA over a 2.
Amanda L. Adler   +9 more
doaj   +1 more source

Coronavirus disease COVID-2019

open access: yesБезопасность и риск фармакотерапии, 2020
The paper presents data on the coronavirus diseaseCOVID-2019 caused by the SARS-CoV-2 coronavirus, which was temporarily named 2019-nCoV (2019 novel coronavirus) until 11 February 2020.
B. K. Romanov
doaj   +1 more source

Identification of individuals with gonorrhoea within sexual networks: a population-based study.

open access: yes, 2006
BACKGROUND: Molecular typing of Neisseria gonorrhoeae and contact tracing provide a combined approach for analysis of sexual networks in metropolitan areas, although there are some difficulties in application.
Bishop, Cynthia J   +7 more
core   +1 more source

Home - About - Disclaimer - Privacy